Journal article icon

Journal article

Thymosin-β4: A key modifier of renal disease

Abstract:

Introduction: There is an urgent need for new treatments for chronic kidney disease (CKD). Thymosin-β4 is a peptide that reduces inflammation and fibrosis and has the potential to restore endothelial and epithelial cell injury, biological processes involved in the pathophysiology of CKD. Therefore, thymosin-β4 could be a novel therapeutic direction for CKD.

Areas covered: Here, we review the current evidence on the actions of thymosin-β4 in the kidn...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1080/14712598.2018.1473371

Authors


More by this author
Role:
Author
ORCID:
0000-0002-1940-0333
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Physiology Anatomy and Genetics
Oxford college:
Jesus College
Role:
Author
ORCID:
0000-0002-9862-7332
More by this author
Role:
Author
ORCID:
0000-0001-6580-3435
More from this funder
Grant:
MR/J003638/1
MR/P018629/1
Publisher:
Taylor & Francis Publisher's website
Journal:
Expert Opinion on Biological Therapy Journal website
Volume:
18
Issue:
sup1
Pages:
185-192
Publication date:
2018-05-04
Acceptance date:
2018-05-02
DOI:
EISSN:
1744-7682
ISSN:
1471-2598
Pubs id:
pubs:853152
URN:
uri:1618399c-2d94-44d8-bb71-c6630fa237ff
UUID:
uuid:1618399c-2d94-44d8-bb71-c6630fa237ff
Local pid:
pubs:853152

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP